Mid-term Clinical Results of Tissue-Engineered Vascular Autografts Seeded with Autologous Bone Marrow Cells.
10.3349/ymj.2004.45.Suppl.73A5
- Author:
Toshiharu SHIN'OKA
1
Author Information
1. Department of Cardiovascular Surgery, Tokyo Women's Medical University, Tokyo, Japan. ssinoka@hij.twmu.ac.jp
- Publication Type:Brief Communication
- Keywords:
Tissue-engineered vascular autografts;
bone marrow cells
- From:Yonsei Medical Journal
2004;45(Suppl):S73A5-S74A5
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Prosthetic and bioprosthetic materials currently in use lack growth potential and therefore must be repeatedly replaced in pediatric patients as they develop. Tissue engineering (TE) is a new discipline that offers the potential for creating replacement structures from autologous cells and biodegradable polymer scaffolds. In May 2000 we initiated clinical application of tissue-engineered vascular grafts seeded with cultured cells. However, cell culturing is time-consuming and xeno-serum must be used. To overcome these disadvantages, we started the usage of bone marrow cells (BMCs), readily available on the day of surgery, as a cell source. The aim of the study was to assess the safety and feasibility of this technique for creating pulmonary artery conduits. METHODS: Since August 2000, TE grafts seeded with autologous BMCs have been implanted in thirty-five patients. The patients and/or their parents were fully informed and had given consent to the procedure. Five ml/kg of bone-marrow was aspirated under general anesthesia prior to the skin incision. The polymer tube serving as a scaffold for the cells was composed of a co-polymer of l-lactide and epsiloncaprolactone (PCL-PLA, 50:50). This co-polymer is degraded by hydrolysis. The matrix is 80% porous and the diameter of each pore is 100-200micro M Polyglycolic acid (PGA) woven fabric with a thickness of 0.5 mm was used for reinforcement. Twenty-one TE conduits (TCPC grafts) and fourteen TE patches were used for the repair of congenital heart defects. The patients' ages ranged from 1 to 24 years (median, 5.5 years). All patients underwent a catheterization study and/or computed tomography (CT) scans for evaluation after operation. The patients received anticoagulation therapy for 3 to 6 months after surgery. RESULTS: Mean follow-up after surgery was 424 days (maximum, 38 months). There were no complications such as thrombosis, nor stenosis or obstruction of the tissue-engineered autografts. One late death at 3 months after TCPC was noted in HLHS patients, which was unrelated to the TE graft. There was no evidence of aneurys formation on cineangiography or CT. On examination in late period, all tube grafts were patent, and the diameter of the tube graft increased over time. (110 +/- % of the implanted size) CONCLUSIONS: Biodegradable conduits or pulmonary vessel patches seeded with autologous BMCs showed normal function (good patency up to maximum follow-up of 38 months). As living tissues these vessels may have the potential for growth, repair and remodeling. The TE approach may provide an important alternative to the use of prosthetic materials in the field of pediatric cardiovascular surgery. Longer follow-up is necessary to confirm the feasibility of this approach.
